Injectable cardiac tissue engineering for the treatment of myocardial infarction.
Injectable cardiac tissue engineering for the treatment of myocardial infarction.
复制标题
DOI：
10.1111/j.1582-4934.2010.01046.x
复制
发表时间：
2010-05
影响因子：
5.3
通讯作者：
Wang C
中科院分区：
文献类型：
--
作者：
Wang H;Zhou J;Liu Z;Wang C
心脏病是全球发病率和死亡率的主要原因。心肌梗死导致心脏组织的永久性丧失，最终导致心力衰竭。然而，目前的治疗方法只能阻止疾病的进展。因此，需要新的疗法来再生受损的心脏，以克服心力衰竭患者的不良预后。心脏捐献者的短缺也是创新新疗法的一个因素。虽然基于细胞的治疗的心脏性能已经得到改善，但不令人满意的细胞保留和移植存活仍然困扰着这项技术。由于生物材料可以改善细胞的保留，存活和分化，心脏组织工程目前正在探索作为一种方法，以支持基于细胞的治疗和提高其对心脏疾病的疗效。在过去的十年中，心脏组织工程学取得了长足的进步。在心脏组织工程的各种方法中，可注射心脏组织工程方法比体外工程组织或心外膜补片植入方法更具微创性。因此，它在临床上很有吸引力。本文就可注射心脏组织工程的种子细胞来源、生物材料、临床前研究和临床应用等方面的最新进展作一综述。其余的问题也将讨论。
Heart disease is a leading cause of morbidity and mortality worldwide. Myocardial infarction leads to permanent loss of cardiac tissue and ultimately heart failure. However, current therapies could only stall the progression of the disease. Thus, new therapies are needed to regenerate damaged hearts to overcome poor prognosis of patients with heart failure. The shortage of heart donors is also a factor for innovating new therapies. Although the cardiac performance by cell-based therapy has improved, unsatisfactory cell retention and transplant survival still plague this technique. Because biomaterials can improve the cell retention, survival and differentiation, cardiac tissue engineering is now being explored as an approach to support cell-based therapies and enhance their efficacy for cardiac disease. In the last decade, cardiac tissue engineering has made considerable progress. Among different kinds of approaches in the cardiac tissue engineering, the approach of injectable cardiac tissue engineering is more minimally invasive than that of in vitro engineered tissue or epicardial patch implantation. It is therefore clinically appealing. In this review, we strive to describe the major progress in the flied of injectable cardiac tissue engineering, including seeding cell sources, biomaterials and novel findings in preclinical studies and clinical applications. The remaining problems will also be discussed.
登录
查看更多内容
DOI：
10.1084/jem.20061916
发表时间：
2007-02-19
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Behfar A;Perez-Terzic C;Faustino RS;Arrell DK;Hodgson DM;Yamada S;Puceat M;Niederländer N;Alekseev AE;Zingman LV;Terzic A
通讯作者：
Terzic A
影响因子：
24
作者：
Dai, WD;Wold, LE;Kloner, RA
通讯作者：
Kloner, RA
影响因子：
--
作者：
Huang, NF;Yu, JS;Lee, RJ
通讯作者：
Lee, RJ
DOI：
10.1111/j.1582-4934.2006.tb00401.x
发表时间：
2006-04
影响因子：
5.3
作者：
Chalfoun CT;Wirth GA;Evans GR
通讯作者：
Evans GR
影响因子：
--
作者：
Barile, Lucio;Chimenti, Isotta;Giacomello, Alessandro
通讯作者：
Giacomello, Alessandro